UNSPSC 51182706: Metformin/repaglinide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182706 Metformin/repaglinide is a Commodity code whose nominal scope — pharmaceutical products for diabetes management — does not align with the recent state and local procurement activity tagged under it. The single recent opportunity in the dataset is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, which solicits naloxone and safe drug deactivation systems for community health initiatives, not metformin or repaglinide products. This mismatch suggests either a tagging error in the county's classification or a divergence between the code's intended scope and its current real-world application at the issuing jurisdiction.

The Seminole County solicitation requires 1,900 units of naloxone and 800 safe drug deactivation systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, with response due July 26, 2023. The contract includes a two-year initial term with one-year renewal option, fixed-fee pricing, E-Verify compliance, drug-free workplace certification, and specified insurance coverage (workers' compensation, commercial general liability, professional liability). The procurement may draw FEMA funding and subjects vendors to federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations are noted. Based on this single recent opportunity, the code shows minimal relevant activity for metformin or repaglinide procurement in state and local markets; business development professionals should verify UNSPSC classification with target jurisdictions before pursuing opportunities tagged under this code.